Adding to ADC port­fo­lio, As­traZeneca en­ters po­ten­tial $600M li­cens­ing deal with Chi­nese start­up

As­traZeneca is pay­ing up to Shang­hai-based LaNo­va Med­i­cines for one of the biotech’s pre­clin­i­cal stage an­ti­body-drug con­ju­gates (ADC), dubbed LM-305, fol­low­ing a li­cens­ing deal ear­li­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER